Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RLFTF RELIEF ANNOUNCES NOTICE OF ANNUAL GENERAL MEETING OF RELIEF THERAPEUTICS HOLDING AG 27 May 2021
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
Geneva, Switzerland, May 27, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company" , a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today gives notice of the Annual General Meeting (AGM) of shareholders to be held on June 18, 2021.
As a result of the exceptional circumstances due to the coronavirus pandemic, the AGM will be held without the physical presence of shareholders in accordance with article 27 of the Ordinance 3 on Measures to Combat the Coronavirus. Guidelines on how to deliver voting instructions can be found in the AGM formal invitation, which is being sent out today to registered shareholders.
Agenda items:
1. Approval of the Annual Report, Statutory Financial Statements (balance sheet, income statement and notes) and Consolidated Financial Statements for the year 2020, Statutory Auditors' Report
2. Appropriation of Results
3. Discharge of the members of the Board of Directors and of the Executive Committee
4. Increase of the authorized share capital
5. Increase of the conditional share capital
6. Votes on the compensation of the members of the Board of Directors and of the Executive Committee
7.1 Re-election of existing members of the Board of Directors
7.2 Election of new members of the Board of Directors - Dr. Patrice P. Jean and Paolo Galfetti
7.3 Re-election of the Chairman of the Board of Directors
7.4 Re-election of the members of the Nomination and Compensation Committee
7.5 Re-election of the Independent Voting Rights Representative
7.6 Re-election of the Auditors
The full agenda is available for download on the Company’s website (https://relieftherapeutics.com/investor-relations).
The Board of Directors recommends that the General Meeting approves the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for the year ended 31 December 2020.
The Board of Directors proposes to carry forward the loss for the year 2020 in the amount of CHF 20'009'867.
The Board of Directors recommends that the General Meeting grants discharge to the members of the Board of Directors and of the Executive Committee.
Increase of authorized capital and of conditional share capital
The authorized share capital is intended for the future financing of the Company, as required in connection with future projects as well as for responding quickly to strategic business opportunities.
The Board of Directors proposes to maintain an authorized share capital of around but not more than 50% of the ordinary share capital and, therefore, to increase the amount of the existing authorized share capital from CHF 11'250'000.00 to CHF 16'850'000.00.
Like the authorized share capital, conditional capital 3b2 provides the Company with the flexibility to quickly obtain financing but allows for the use of certain financial instruments carrying derivative features.
The Board of Directors proposes to maintain a total conditional share capital of around but not more than 50% of the ordinary share capital and, therefore, to increase the amount of the existing conditional share capital from CHF 2'533'413.33 to CHF 15'630'000.00.
Votes on the compensation of the members of the Board of Directors and of the Executive Committee
The Board of Directors recommends a maximum amount of CHF 1'500'000 (both fixed and variable compensation, including stock options and other, but excluding employer social security contributions) for the members of the Board of Directors for the period from the 2021 AGM until the 2022 AGM and a maximum total compensation of CHF 5'000'000 for the members of the Executive Committee for the financial year 2022.
These compensation amounts are the same amounts approved by the December 2020 Extraordinary General Meeting for the prior period (from the 2020 AGM until the 2021 AGM for the Board compensation and for financial year 2021 for the Executive Committee compensation).
The Board of Directors proposes to re-elect: (i) the members of the Board of Directors (Dr. Raghuram Selvaraju and Dr. Thomas Plitz), (ii) the members of the Nomination and Compensation Committee (Dr. Raghuram Selvaraju and Dr. Thomas Plitz), (iii) the Chairman of the Board of Directors (Dr. Raghuram Selvaraju), (iv) the Independent Voting Rights Representative (Thomas Hua), and (v) the Auditors (MAZARS SA).
Election of Dr. Patrice P. Jean as new member of the Board of Directors
Dr. Patrice P. Jean is the Chair of the Life Sciences Practice at Hughes Hubbard & Reed, an international law firm based in New York City.
She has over a decade of experience counselling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law, including asserting and defending patent rights underlying core technologies and innovations. Dr. Jean graduated summa cum laude from Xavier University of Louisiana in 1993 with a degree in biochemistry, and she holds a Ph.D. in molecular biology from Princeton University.
She graduated from Columbia University School of Law in 2002, where she was Editor-in-Chief of the Columbia Science & Technology Law Review. Dr. Jean currently serves as Vice-President of the New York Intellectual Property Law Education Foundation and is a Board member of the New York Intellectual Property Law Association.
Election of Paolo Galfetti as new member of the Board of Directors
Paolo Galfetti is the Chief Executive Officer of APR Applied Pharma Research S.A. (APR). Under the recently signed binding term sheet between Relief and APR, APR is entitled to appoint a designee to serve on the Relief Board of Directors. Mr. Galfetti has over twenty years of management experience in the pharmaceutical sector, including in the areas of business development and licensing, operational strategic management, clinical research, and pharmaceutical discovery and development.
He joined APR in 1995 as head of licensing and business development and was appointed Chief Executive Officer (CEO) in 2002. Under his leadership, APR has brought its first product onto the market and developed a rich pipeline of product candidates. He also was a founding partner, CEO and board member of the Institute for Pharmacokinetic and Analytical Studies AG (IPAS), a Swiss contract research organization (CRO), as well as CEO and board member of Farma Resa s.r.l., an Italian CRO. Mr. Galfetti is a Chartered Financial Analyst (CFA) and has a bachelor’s degree in economics from the Commercial University Bocconi, Milan, Italy. He is a member of several pharma licensing groups.
###
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.
Contact:
CONTACT:
RELIEF THERAPEUTICS Holding AG:
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
contact@relieftherapeutics.com
For media inquiries contact:
MEDIA/INVESTOR CONTACT:
MC Services AG
Anne Hennecke
Tel.: +49 (0) 211-529-252-22
relief@mc-services.eu
https://www.relieftherapeutics.com/newsblog/relief-announces-notice-of-annual-general-meeting-of-relief-therapeutics-holding-ag
$RLFTF DD by Bert-Jan on Yh0 - From the collaboration agreement (take a look at the last sentence):
NeuroRx shall receive 20% of Net Profits and Relief shall receive 80% of Net Profits from the Product sales in the ROW Countries.
Relief shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the ROW Countries consistent with GAAP.
NeuroRx shall have the right (itself or through an independent auditor) to audit Relief’s books and records to confirm the Net Profits from Relief’s sales of Product in the ROW Countries.
Should Relief request assistance from NeuroRx in clinical development, manufacture, or commercialization, NeuroRx shall be entitled to additional consideration as agreed between the Parties.
#NeuroRx $RLFTF $BRPA #TheMath
GENEVA, Switzerland and RADNOR, Pa. , Sept. 21, 2020 /PRNewswire/ --
RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) Relief Therapeutics and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil)
(Zyesami ) worldwide.
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
They have agreed that NeuroRx will lead commercialization in the United States , Canada , and Israel , while Relief will lead commercialization in Europe and the rest of the world.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
https://www.prnewswire.com/news-releases/relief-and-neurorx-announce-partnership-for-global-commercialization-of-rlf-100-and-selection-of-commercial-partners-301134379.html
$RLFTF (related) If you want to follow the meeting : https://www.cstproxy.com/bigrockpartners.2021/
It's now.
.. many posts already saying approved on various boards..
Dr J and Ram take turns... GEM rolls out the carpet.
$RLFTF (VIP related) DD by Mathieu on Yh-0 - Imagine if you could invest in the company who has the patent on a synthetic VIP.
https://youarethehealer.org/mold-and-toxins/moldy-people/testing-for-mold-illness/vasoactive-intestinal-peptide/
https://www.frontiersin.org/articles/10.3389/fncel.2019.00421/full
https://www.prohealth.com/library/vasoactive-intestinal-peptide-vip-treatment-the-key-to-100-recovery-from-mold-ilness-41086
https://www.nature.com/articles/s41467-019-08427-3.pdf
https://www.eurekaselect.com/168911/article
The science has almost figured it out. Soon to discover Aviptadil.
https://directorsblog.nih.gov/2021/05/11/how-severe-covid-19-can-tragically-lead-to-lung-failure-and-death/
$RLFTF (related) DD by Serge on Yh0 - Just for information, for all new boardmembers. Aviptadil is not only targetting Covid 19
VIP is shown to have important potential effects in the treatment of other lung diseases including Chronic Obstructive Pulmonary Disease
(“COPD”), Sarcoidosis, asthma/allergy, and Chronic Respiratory Inflammation Syndrome.
NeuroRx intends to research the use of VIP in these and other conditions in the future.
VIP is also known to be active in the brain and NeuroRx plans to
explore its potential use in the treatment of Huntington’s Disease, Multiple Sclerosis, and other CNS diseases if an
appropriate mechanism of CNS delivery can be developed
$RLFTF DD (opinion) by Pensenmarkt on Yh0 - Just read the doc file of BRPA. Rlf were mentionned several times!!!! Chill out guys, our time will come! Trust the process and most important, trust RAM and our product! GLTA
$RLFTF rk on Yh0 Todays Woodland Report:
Shares of Big Rock Partners Acquisition (BRPA) surged on high volatility and has received a couple trade halts in early market trading.
Currently, BRPA is a special acquisition company or SPAC that announced a couple months ago its intended merger with molecule pharmaceutical company NeuroRx, the company excels at rapid development of already-known molecules to deliver lifesaving solutions in record time at minimum cost. The proposed business combination between the two companies, if approved by the stockholders of BRPA and NeuroRx, is currently expected to close in Q2 2021.
One molecule that the company is developing is Zyesami (or Aviptadil/RLF-100), created, developed and patented by Relief Therapeutics (RLFTF) for the treatment of COVID-19 related lung injury and acute respiratory failure.
To sum it all up, Zyesami’s clinical trials showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells.
Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.
$LWLG Lightwave Logic to Share Business Update Presentation Immediately Following Conclusion of Annual Shareholder Meeting
Video Presentation by CEO Dr. Michael Lebby to be Posted to Company Website
ENGLEWOOD, Colo., May 19, 2021 -- Lightwave Logic, Inc. (OTCQX: LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at higher speeds with less power, today announced that a business update presentation will be posted to the Company’s website immediately following the conclusion of the annual shareholder meeting.
The video presentation will be posted to the following page for public viewing: https://www.lightwavelogic.com/resource-center/technical-presentations-white-papers/
“I look forward to providing a comprehensive business update to our valued shareholders, illustrating our continued progress towards commercialization of our innovative technology,” said Dr. Michael Lebby, CEO of Lightwave Logic. “While the annual shareholder meeting pertains to shareholder voting matters, the posting of this pre-recorded presentation will serve as a proper venue for our shareholders to hear from the CEO directly as to our latest business achievements and to answer common questions we hear from the investment community.
“We look forward to a post-pandemic environment, where we can once again meet shareholders in-person for business update presentations from the Lightwave Logic management team,” concluded Lebby.
About Lightwave Logic, Inc.
Lightwave Logic, Inc. (OTCQX: LWLG) is developing a platform leveraging its proprietary engineered electro-optic (EO) polymers to transmit data at higher speeds with less power. The Company's high-activity and high-stability organic polymers allow Lightwave Logic to create next-generation photonic EO devices, which convert data from electrical signals into optical signals, for applications in data communications and telecommunications markets. For more information, please visit the Company's website at lightwavelogic.com.
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, lack of available funding; general economic and business conditions; competition from third parties; intellectual property rights of third parties; regulatory constraints; changes in technology and methods of marketing; delays in completing various engineering and manufacturing programs; changes in customer order patterns; changes in product mix; success in technological advances and delivering technological innovations; shortages in components; production delays due to performance quality issues with outsourced components; those events and factors described by us in Item 1.A "Risk Factors" in our most recent Form 10-K; other risks to which our Company is subject; other factors beyond the Company's control.
Investor Relations Contact:
Greg Falesnik or Luke Zimmerman
MZ Group - MZ North America
949-385-6449
LWLG@mzgroup.us
www.mzgroup.us
$RLFTF DD (opinion) post by Currahee on Yh0 We made it to Medscape a reliable source for clinical information ... Only a matter of time fellow Reliefers.
https://www.medscape.com/answers/2500114-197461/what-other-drugs-are-being-investigated-to-treat-ardscytokine-release-associated-with-coronavirus-disease-2019-covid-19
--
MCJoey reply -
Author...Rutgers....David J Cennimo, MD, FAAP, FACP, AAHIVS Assistant Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Rutgers New Jersey Medical School
David J Cennimo, MD, FAAP, FACP, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine, American Academy of Pediatrics, American College of Physicians, American Medical Association, HIV Medicine Association, Infectious Diseases Society of America, Medical Society of New Jersey, Pediatric Infectious Diseases Society
--
MCJoey
"Medscape is the leading online global destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME."
Anddd
"We identify topics for Medscape’s news and perspectives content based on current clinical and professional information needs of physicians and healthcare professionals. This content is produced by a team of seasoned, full-time journalists and editors. Contributing clinical experts collaborate with an experienced team of in-house medical editors on Medscape’s expert perspectives and features content. Medscape editors review all content prior to publication to ensure adherence to our editorial standards, including disclosure of any relevant financial relationships of expert contributors. Further, we do not assign journalists to cover topics in respect of which they have disclosed a financial interest."
$RLFTF whoknows on Yh0 Still in the newest S-4 , on numbered page 190 .....
.
"NeuroRx anticipates delivering the detailed efficacy and safety data requested by FDA for an EUA determination by the end of May 2021 in the eCTD electronic format required by FDA and all regulators who are parties to the International Commission on Harmonization (ICH-10).
If NeuroRx meets this objective, it will have delivered a regulatory file delineating safety and efficacy data of an investigational drug within 3 months of last visit in a clinical trial.
Although there can be no assurance that the FDA will conclude that ZYESAMI meets or exceeds the EUA standard of “may be effective” in the treatment of COVID-19, NeuroRx is hopeful that the FDA will grant EUA to ZYESAMI."
.
.
have a good day , stay safe !
http://filings.irdirect.net/data/1719406/000119312521165626/d56937ds4a.pdf
$RLFTF DD (opinion) by Brian A on Yh0 - Good evening everyone! Forgive me please, if this was already previously posted here.
I just read an article appearing on the internet site, India dot tv, that the Hospital Chairperson of Ganga Ram Hospital in New Delhi, Dr. DS Rana, has said that they are considering dropping Remdesivir as a COVID therapeutic/treatment as, “...there is no evidence of its effectiveness in treating COVID patients.”
https://www.indiatvnews.com/news/india/remdesivir-may-be-dropped-soon-as-there-is-no-proof-of-its-effectiveness-in-treating-covid19-patients-705500
While we already knew this, it further affirms the direction the NIH, FDA, EMA, actual hospital physicians in other countries, (et al) are taking with regard to Aviptadil’s/Zyesami’s future COVID indications.
I am truly of the opinion, as I know many of you are, that Aviptadil/Zyesami WILL become SOC for COVID, and MANY other respiratory ailments, in the US, Europe, their allied countries, and SO MANY other places around the globe.
It’s only a matter of time at this point, as Remdesivir continues to show limited, to no, efficacy against COVID.
We’re going “Prime Time” before you know it. Stay Long and Strong...it’s coming!
—Cheers to All—
,,can't really say.. I've been wrong so many times on this when it comes to expectations that I don't even dare.. but they've been saying all along that w/enough positive data the FDA could grant EUA at any time.. but my gut says money and big corp's are the deciding factors.. sadly
..get the same feeling when I think of Iraq and the big money made by companies who who were lined up to get the side contacts.. who made $$ in Aug-Oct I was hearing about great results and even people avoiding lung transplants... What happened?
..? don't know.. we may get EUA for use w/Rem.. or be moved forward in EU .. If anything we know for sure Big Pharma runs things.. sad.
$RLFTF DD (opinion) by Old) James on Yh-0 - A funny week in several ways. The heavy weight holding us down is either lifted, or much lighter.
But the months of shorting and manipulation of bid/ask, plus general OTC malaise, had their effect.
Hence, almost nobody looked at us this week; we are almost invisible.
BUT, articles coming out daily in medical literature; articles showing our VIP drug is very promising, and vaccines will not solve the C19 problem on their own.
The action here will heat up, and it will heat up -at least some - before the EUA.
$RLFTF (copy) DD by DanG on Yh-0
The FDA has asked for public comment on the safety of Peptides. This could be related to the EUA application and ongoing studies of Aviptadil. Not sure how it might effect either. My guess is it is a precursor to full approval for the use of Aviptadil, as the focus is on safety related to drug interactions and much wider uses than Covid-19 treatment.
Here is the link:
https://www.federalregister.gov/documents/2021/05/14/2021-10179/evaluating-the-clinical-pharmacology-of-peptides-establishment-of-a-public-docket-request-for
$RLFTF DD by nickles on Yh0
I just went through TFFP’s Q1 results transcript and I quote “The feasibility arrangement with NeuroRx is progressing.
TFF has SUCCESSFULLY formulated NeuroRX’s peptide ( for those who don know it’s our peptide Aviptadil or RLF-100) for treating COVID in an inhalable , dry powder optimization work and stability testing of the dry powder is underway.
Its good news anyway!
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS https://clinicaltrials.gov/ct2/show/NCT04536350?term=aviptadil&draw=2&rank=2
$MSTO DD (opinion) by afterhoursearnings on Stktwts
5/7/21
I have a hard time believing that a broker or three are not underwater on this one.....many of the shares that were bought and sold on the big volume day were sold without ownership.
This is not an assumption.
The guy who ran the company prior still holds a good piece of the float as does the current owner.
I also happen to know that the people who started buying at the double bottom back in November hold more shares now than before.
Imo we see a quick dip down before the covering starts....kinda like last big volume day.
The setup here is explosive...particularly with the float staying static.
..yes, the websites for both companies say they're playing nice..
$RLFTF DD Hooter on Yh0 Latest Relief response.
Dear Mr. Hooter:
Like you, we are concerned about the COVID-19 situation in emerging markets. Once we obtain the full data set from the U.S. Ph. 2b/3 study, we intend to reach out to regulators in various markets to discuss options to bring RLF-100 to patients. This could include India.
Kind regards,
Relief Therapeutics
$RLFTF DD by Equalizer on Yh0: Looking at NIH study hospital sponsors more closely,
3 of top 5 medical centers / hospitals in the US are now participating in the study:
Cleveland Clinic (4 of their sites), UCLA, Columbia
And 6 of the top ~30 in the US (Vanderbilt, Duke)
And ALL are in the Top 100
(Intermountain, Univ Utah, Baystate, Univ S Carolina , Wake Forest, also top 100)
(Banner # 2 in AZ)
Montefiore top ranked in NY # 6, higher in Lung and Pulminary
Out of over 6,000 hospitals in the US.
Only 166 hospitals in the US are ranked 1x or more as a top 50
$RLFTF (related) Interesting post from Oct 2020 by Paul W. on FaceBK
NIH commissioned a F1000 Faculty review which was submitted on or around Sept 5th 2019 with a publication of September 12th 2019.
They wanted to study the impact of VIP on gastrointestinal function and diseases based on recent findings, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.
Now, we know that NIH reached out to Relief about RLF-100, it makes sense coming off the cusp of very fresh and recent studies (at that time).
There is NO doubt our Government knows they are into something (we know this) And this review has most probably been reviewed by many of you and further supports the hypothesis that:
1) VIP is a powerful peptide that can be used for multiple treatments
2) it’s on the radar of MANY as a viable therapeutic for a multitude of diseases
3) with the recent discoveries, renewed focus on testing we are just getting started
4) the government has already started studying / reviewing VIP as supported here as well as continued studies around things like influenza (currently in progress) ...and we are a part of it Bottom line, every piece of literature, every review, there is nothing but promise for this drug.
Here are a few excerpts to digest. The article itself is a additional reading material for those still compiling DD
---
Therefore, the immunomodulatory actions of VIP expand its abilities to treat acute and chronic inflammatory and autoimmune diseases, including sepsis 93, multiple sclerosis 94, Crohn’s disease 95, and type 1 diabetes 96.
<< VIP/PACAP and diabetes>>
Therefore, VPAC2 agonists and PAC1 agonists are candidates for the therapy of type 2 diabetes.
<< VIP/PACAP and cancers>>
Therefore, VPAC1 can be a target for anti-cancer drugs, since VPAC1 antagonists inhibit the growth of colonic cancer cell lines in vitro
<< Therapeutic potential of VIP>>
VIP has been suggested to be a therapeutic target for diseases such as diarrhea 58, IBD 95, diabetes 28, autoimmune diseases 115, neurodegenerative disorders 116, lung disease 117, 118, sarcoidosis 119, and cancers.
Finally, VIP-tagged nanoparticles may be a useful strategy for selective drug delivery to VPAC-overexpressing tumor cells and immune cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743256/?fbclid=IwAR1U23ZMRRMBRmGsRFGDygK8kBb_aMIi_W2fzR2J_cA_Z50y7BSU86ln-Jo
$RLFTF DD by Bert-Jan on Yh0
Update on the Activ 3B trial, more locations are recruiting and 3 extra locations added:
https://clinicaltrials.gov/ct2/history/NCT04843761?A=6&B=7&C=merged#StudyPageTop
..hope you're crowded with a hundred ways of healing and are free of this..
$RLFTF DD by WONG on Yh0 - This is so much more than a Covid play and actually much more than just a lung treatment. Found some interesting stuff with Professor Illana Gozes.
There are other indications that may involve VIP as an active drug product including acute and chronic inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohn’s disease or autoimmune diabetes. VIP can actually be used in these
conditions to inhibit the autoimmune response.
In cancer, VPAC1 receptors may be molecular targets for diagnosis, prevention and treatment of breast cancer, as well as lung cancer. Radio labelled VIP analogues have been developed for imaging of lung and breast cancer.
Synthetic VIP receptor antagonists inhibited the proliferation and potentiated the ability of chemotherapeutic agents to cause apoptosis of lung and breast cancer cells. VIP-chemotherapeutic conjugates have been synthesized which bind to VPAC1 receptors and are internalized, resulting in the killing of lung and breast cancer cells.
$RLFTF DD (opinion) by OU3 on Yh0 The virus is mutating and will much more so once the Flu is prevalent again.
This is actually quite frightening but lab research has found that if the Influenza A combines with SARS-CoV-2 we have a very serious problem and treatments targeting ACE2 receptor are key.
Aviptadil could save countless lives and be incredibly valuable to have an impact on both Influenza and SARS-CoV-2.
“The upcoming flu season in the Northern Hemisphere merging with the current COVID-19 pandemic raises a potentially severe threat to public health.
Through experimental coinfection with influenza A virus (IAV) and either pseudotyped or live SARS-CoV-2 virus, we found that IAV preinfection significantly promoted the infectivity of SARS-CoV-2 in a broad range of cell types. Remarkably, in vivo, increased SARS-CoV-2 viral load and more severe lung damage were observed in mice coinfected with IAV.
Moreover, such enhancement of SARS-CoV-2 infectivity was not observed with several other respiratory viruses, likely due to a unique feature of IAV to elevate ACE2 expression.
This study illustrates that IAV has a unique ability to aggravate SARS-CoV-2 infection, and thus, prevention of IAV infection is of great significance during the COVID-19 pandemic.”
Go Aviptadil/Zyesami!
I am less concerned about our future knowing we have this drug so close to approval. See reply for citation link.
https://www.nature.com/articles/s41422-021-00473-1
$RLFTF DD (opinion) by appie on Yh0 - Covid is unfortunately far from over and this is certainly going to take a long time. this is because 1 in 4 people in rich countries have had a vaccination.
In poorer countries 1 in 500 have had a vaccination.
WHO is assuming that the virus is going to mutate into a more contagious and deadly variant in the poorer countries so there will be more infections and deaths in the rest of the world.
Aviptadil is urgently needed and the demand will only increase in the future. so be patient and the approval is going to come sooner or later making this SOC in all countries around the world!
---
Michael
ARDS can occur separately from covid.
---
Bradley
Very far from over. I agree. I can’t find it, it was old dd, but when they first discovered vip in the beginning they throughout the years documented things it could help with brain functions/strokes, there were about 20 different things. This is going to be a one of the biggest breakthroughs in a long time and I am thrilled to be part of it.
Press release 6 May 2021 Brussels - Coronavirus: Commission proposes EU Strategy for the development and availability of therapeutics
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_2201?fbclid=IwAR2YUzo8Lu77hdl6eMR71QI5Q0c7HVjo55yfTbTZLVtT1szGQ2thgXV8P4A
Press release 6 May 2021 Brussels - Coronavirus: Commission proposes EU Strategy for the development and availability of therapeutics
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_2201?fbclid=IwAR2YUzo8Lu77hdl6eMR71QI5Q0c7HVjo55yfTbTZLVtT1szGQ2thgXV8P4A
YW, just copies.. good info from others
also Mav This is what I got today:
Thank you for your recent e-mail. You asked about the dispute between Relief and NeuroRx. What we can say is that Relief is actively and constructively striving to find an amicable solution to resolve the dispute. Despite the dispute, we believe that both parties remain committed and continue to work to bring RLF-100 (aviptadil) forward.
Kind regards,
Relief Therapeutics
$RLFTF DD by Hooter86 on Yh-0 12 hours ago Relief response email
Dear Mr. Hooter:
Thank you for your e-mails. We will try to address as many of your recent questions as we are able to.
Regarding the binding collaboration agreement between Relief Therapeutics and NeuroRx entered into in September 2020, the agreement has not been changed. According to the agreement, Relief is entitled to 50% of the net profits from the sales in the NeuroRx territory, which includes the U.S., Canada and Israel. As to the dispute with NeuroRx, Relief is actively and constructively striving to find an amicable solution to resolve the dispute.
Regarding the US EUA, under the collaboration agreement, NeuroRx is responsible for the clinical development of RLF-100 in the U.S. NeuroRx has informed us that they are in the process of applying for an EUA. We cannot speculate on how long this process will take.
You asked about whether Relief is funding the U.S. inhaled trial. Relief has always been willing and able to fund the inhaled trial, upon NeuroRx presenting a detailed budget containing appropriate line items and underlying amounts and upon NeuroRx answering reasonable questions that we have posed to them asking for more details about their proposed trial budget. This has not happened to date. Nevertheless, we would also like to point out that Relief has already funded substantial expenses associated with NeuroRx's U.S. inhaled trial.
Regarding the IP around RLF-100, Relief owns U.S. Patent No. 8,178,489, related patents derived from U.S. Patent Application Serial No. 11/817,867 and foreign formulation patents, which are being utilized under the collaboration agreement. Under this agreement, all new and additional IP obtained by NeuroRx related to aviptadil must be cross-referenced by Relief (and vice versa).
While it is our position that we own the IP for RLF-100, it doesn’t matter. NeuroRx has no IP, to our knowledge, that it has licensed or developed regarding aviptadil under any scenario. If any exists and relates to the project contemplated by the collaboration agreement, it is covered by the collaboration agreement.
Kind regards,
What's with all these PR's on Yh-0? SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Northwest Biotherapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
------
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Northwest Biotherapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
---------
If the data is positive then they don't have to reveal anything .. right?
..I'm guessing the headlines about are about keeping people in the dark over TLD..
$RLFTF (related) from flystuffz on Yh-0
Remdesivir received and still maintains full FDA approval while being recommended against by the WHO who conducted their own more extensive trial. Meanwhile Aviptadil is still struggling to receive an EUA while the FDA has no other therapeutics besides Remdesivir to treat Covid. Further there's now a trial testing exclusively Aviptadil and Remdesivir together as promising drugs for efficacy yet one of them is fully FDA approved while the other still is only available under EAP.
Are FDA waiting for results from the NIH trial to make a determination because it all kind of stinks if that's the case. Possibly the NeuroRx $BRPA data could have been misrepresented?, but everything we've been told says that Aviptadil is definitely safe and could be effective. It could be that the second EUA application still hasn't been submitted or only has been submitted recently which in that case management has grossly misrepresented the timetable for submission.
Drug approval of rlf-100/aviptadil/zyesami is literally THE most important catalyst. IP disputes, profit disagreements, delays, unprofessional communication, drug naming, whatever else pales in contrast to if and when approval will come. What is the status of the EUA submission? That is the absolutely most important question and none of us know the answer to unfortunately.
..sounds good.
$RLFTF (related) "My LIMITED opinion" I've been looking at FDA hearings from December w/attempts by Dr's to get various therapeutics accepted and I'm starting to think all the things perceived as shady by Dr J are really apart of the kind of approach needed to be accepted and I'm starting to think he's been on a high-wire actually and not trying to rip anyone off (IMO).. a hint that it may be working is the Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir and I'm sure He and others are disturbed by the wait.
https://www.neurorxpharma.com/neurorx-announces-zyesami-aviptadil-has-been-selected-for-inclusion-in-nih-sponsored-global-clinical-trial-to-include-aviptadil-and-remdesivir/